Revolution Medicines shares surged after the company reported clinical trial results described as unprecedented for its cancer treatment program. The move reflects a significant market repricing of the company's pipeline value, with investors responding to data that stood out against existing benchmarks in oncology drug development. Revolution Medicines operates in the RAS-targeted therapy space, one of the most competitive and historically difficult segments of cancer drug development, where meaningful efficacy signals have been rare. Strong trial readouts in this category typically trigger rapid revaluation because RAS mutations drive a large share of hard-to-treat cancers, including pancreatic and lung cancers, creating a broad potential patient population. Positive data at this stage compresses the perceived risk of late-stage failure and raises probability-weighted revenue estimates for analysts modeling peak sales. The results position Revolution Medicines more credibly against larger oncology players and could attract partnership or acquisition interest. Near-term focus will be on regulatory pathway clarity, confirmatory trial design, and whether the efficacy profile holds across tumor subtypes.
Indian startups raised $5.2 billion across 501 deals in H1 2026, down 9% in value but up 7% in deal count year-on-year, per the Inc42 Indian Tech Startup Funding Report. The drop is driven by fewer mega-rounds, while AI funding surged 317% and growth-stage deal activity hit a multi-year high.
The BSE Sensex fell 893 points and the Nifty 50 shed 279 points on June 30, 2026, wiping out roughly Rs 6 lakh crore in investor wealth in a single session. Both indices dropped 1.16%, closing at 76,200.68 and 23,824.10 respectively.
Kotak Mahindra Bank shares fell nearly 3% to Rs 397.6 after CEO Ashok Vaswani announced plans to exit the bank. Investor concern now centres on succession timing and whether the bank's ongoing digital and deposit-growth strategy will stay on track.
South Korea's Kospi dropped 3% at Monday's open while Japan's Nikkei fell 1%, as escalating US-Iran conflict triggered a broad risk-off move across Asian markets. South Korea's heavy reliance on Middle East oil imports makes it especially vulnerable to geopolitical shocks of this kind.
